Factsheets on COVID-19 Vaccines

In partnership with the Asian Development Bank, IVAC developed factsheets summarizing key measures for COVID-19 vaccines such as effectiveness and protection against severe disease.

The factsheets include:

Duration of Protection of COVID-19 Vaccines against Omicron (November 2022)

Download Here

Key Facts:

COVID-19 vaccines work less well against Omicron than other variants
Vaccine protection against symptomatic disease drops quickly
Protection against severe disease, like hospitalization and ICU admission, is better and durable for many months
A booster shot substantially improves protection against Omicron infection and disease
Booster protection against severe disease lasts for many months
Booster protection against symptomatic disease declines quickly

Effectiveness of COVID-19 mRNA Vaccines Against Omicron (November 2022)

Download Here

Key Facts:

COVID-19 mRNA vaccines are highly effective but are less effective against Omicron than other variants
After the primary mRNA vaccination series: Protection against Omicron symptomatic disease (disease of any severity) drops quickly; and, protection against severe disease is better than that for symptomatic disease and declines some over many months
After a booster shot (3rd dose) of mRNA vaccine: Protection against Omicron symptomatic disease improves substantially but then drops quickly; and, protection against Omicron severe disease improves to >80% on average and declines some over many months.
COVID mRNA vaccines are safe and severe adverse reactions are rare: myocarditis has been detected after mRNA vaccination in rare cases mostly in boys 12-15 years; and, Bell’s Palsy is possibly associated with mRNA vaccines.

Effectiveness of COVID-19 Inactivated Vaccines Against Omicron (November 2022)

Download Here

Key Facts:

COVID-19 inactivated vaccines protect against severe disease, but poorly protects against infection with Omicron.
Effectiveness of the primary vaccination series: protection against Omicron symptomatic disease (of any severity) is low; and, protection against Omicron severe disease is better than for symptomatic disease and lasts for many months.
After a booster shot (3rd dose) of an inactivated vaccine: protection against Omicron symptomatic disease remained LOW with a booster dose of inactivated vaccine; and, protection against Omicron severe disease improves to >70% and lasts for several months.
After a booster shot with an mRNA vaccine: protection against Omicron severe disease and symptomatic disease improved substantially but drops quickly for symptomatic disease.

Next Generation COVID-19 Vaccines

Download Here

Key Facts:

Next-generation or second-generation vaccines are vaccines that are beginning to be available now that may offer improvements on the first wave of COVID-19 vaccines in several areas:

Providing better and longer lasting protection against COVID-19, especially against new variants
Fewer side effects, for example by giving smaller doses
Easier to give to people, such as with needle-free vaccines
Less expensive, achieved with new low-cost manufacturing

Effectiveness of COVID-19 Vaccines Against Omicron in Children (6 months to 18 years)

Download Here

Key Facts:

While infection rates are similar in adults and children, SARS-CoV-2 rarely causes severe disease in children.
Effectiveness of the primary vaccination series: (1) Against severe disease, mRNA vaccines provide good protection and inactivated vaccines provide moderate protection, but some declines are seen by six months; (2) Protection against symptomatic disease and infection (of any severity) is lower and wanes rapidly
After a booster shot (3rd dose) of an mRNA vaccine: (1)Protection against severe disease improved and remained high for 2-3 months; (2) Protection against infection or symptomatic disease was good immediately after vaccination but fell substantially within 1-3 months.

Effectiveness of COVID-19 Viral vector Vaccines Against Omicron

Download Here

Key Facts

After the primary vaccination with vector vaccines: (1) Protection against Omicron symptomatic disease (disease of any severity) ranges from low to moderate; (2) Protection against severe disease is better than that for symptomatic disease but declines some over 6 months.
After a booster shot (3rd dose) of vector or mRNA vaccine: (1) Protection against Omicron symptomatic disease is 63% on average initially, but declines to ~40% by 4 months; (2) Protection against Omicron severe disease improves to 92% on average and declines slightly to 86% by 4 months.